We studied on hematological parameters, lymphocytes distribution and stem cell (CD34 positive) count from cord blood of 43 healthy newborn at obstetrics department, Bach Mai hospital. The result showed that, stem cell count of cord blood is high (16.2% of nucleated cell, equal to 2.4+/- 0.3 G/l). this will be useful to allegoric stem cell transplantation. However, relatively high count of white cell (especially T lymphocyte) can be considerable to procedure and transplant result, free of graft versus host disease.
Fetal Blood ; Bone Marrow Transplantation

On January and June, 2002 four Cord Blood Transplantations were implemented at HCMC Blood Transfusion Hematology Center with ALL, AML, CML and (Thalassemia, where a relation and three unrelation, Results: ANC>0.5x109 L/L: 21 days (relation) and 45 days (unrelation). Platelet count of >50x109 L/L: 27 days (relation) and 60 days (unrelation).
Cord Blood Stem Cell Transplantation ; Fetal Blood

BACKGROUND: Cord blood has been established as an alternative source of hematopoietic reconstituting cells for allogeneic transplantation. CHA cord blood bank, I-CORD has been followed the 'Rubinstein method', which is manual method for collecting mononuclear cells (MNCs). The problem of these manual methods are the risk of bacterial contamination and poor reliability. Recently, an automated method running on the Sepax(R) system (Biosafe S.A., Eysins, Switzerland) has been developed and we compared the results of automated system and manual technique. METHODS: For the total 40 cord blood donations to CHA cord blood bank I-CORD, we processed with manual method using Rubinstein protocol or automated method using "Sepax(R)" (Biosafe S.A.). The recovery rate of total leukocytes and mononuclear cells and hematocrit ratio were compared after processing. RESULTS: The mean ratio of hematocrit after/before processing was significantly lower in samples processed by using manual method (0.96+/-0.42) than "Sepax(R)" (1.4+/-0.4). The WBC recoveries were comparable between two groups (82.8+/-12.8% with manual method and 83.9+/-8.9% with "Sepax(R)"). The recoveries of mononuclear cells were more efficient in samples processed by "Sepax(R)" (100.8+/-31.8%) than those by manual method (74.2+/-13.8%). CONCLUSION: The automated technique using "Sepax(R)" achieved a comparable recovery rate to conventional manual method and has advantages because these systems are more standardized and closed system. The processing effectiveness could be improved through more practices.
Fetal Blood* ; Hematocrit ; Leukocytes ; Running ; Transplantation, Homologous

From Jan.2002 to Nov.2003, umbilical cord blood was collected, screened and processed at HCM City Blood Transfusion and Hematology Hospital for preparing to transplant. The Tokyo Umbilical Cord Blood Bank protocol of collecting, screening, processing and freezing were abided strictly, therefore, the obtained results were consistent with international literature. A stable procedure was established for the proper processus of UCB collection, screening and processing to meet the need of management of hereditary and malignant pathologies in Viet Nam
Fetal Blood ; Blood ; Cord Blood Stem Cell Transplantation

Blood Banks ; Cord Blood Stem Cell Transplantation ; Fetal Blood ; Humans

No abstract available.
Cord Blood Stem Cell Transplantation* ; Fetal Blood* ; Umbilical Cord*

No abstract available.
Cord Blood Stem Cell Transplantation* ; Fetal Blood* ; Humans ; Leukemia* ; Siblings*

Human umbilical cord blood (CB) is one potential source of hematopoietic stem cells (HSC) and progenitor cells, and it has been used to successfully treat leukemia, lymphoma, myelodysplastic syndrome, aplastic anemia, hemoglobinopathies, metabolic storage diseases, and immunodeficiencies. With the establishment of CB bank and increased cases of CB transplantation in clinical use, more and more parents today choice to donate the CB to a public CB bank, or to keep and store the CB in a private bank for potential use in the future. In this article, the current status of CB preservation and clinical application of CB for personal use are reviewed.
Blood Preservation ; Cord Blood Stem Cell Transplantation ; Fetal Blood ; Humans ; Transplantation, Autologous

The number of umbilical cord blood transplantation is increasing worldwide as it has expanded the ability of the transplantaion community to meet the growing needs of their patients. Clinical data over the last decade show promising results in transplantation using both related as well as unrelated cord bloods. Cord blood banks are essential for the clinical use for transplantation and are now established around the world with the major efforts to standardize banking in collection, processing and distribution of cord blood for providing the highest quality stem cells for the patients. In Korea, Medipost, Histostem and some regional cord blood banks were established some years ago and collected thousands of cord blood for public but it had some limitations and was not expanded as the cord blood transplantation was not covered by medical insurance. Recently with the change in the policy of medical insurance to cover the cord blood transplantation, several venture companies are showing great interests in cord blood banking and trying to establish private cord blood banks in Korea. This review article discusses the current status of cord blood transplantaion and also the clincial use of stem cells from cord blood.
Fetal Blood* ; Humans ; Insurance ; Korea ; Stem Cells ; Transplantation ; Umbilical Cord*

OBJECTIVEThis review discussed the available data on treatment outcomes of cord blood transplantation (CBT) for acute leukemia.

DATA SOURCESThe data cited in this review were obtained from articles listed in Medline and Pubmed.

STUDY SELECTIONWe reviewed the articles of clinical results from various registries and institutions, as well as our experiences with CBT in children, adolescents and adults.

RESULTSThis research has clearly shown that cord blood (CB) has several unique characteristics resulting in distinct advantage and disadvantages when compared to transplantation with unrelated donor bone marrow or peripheral blood stem cells. The field of CBT has advanced from investigating its safety and feasibility to addressing more specific issues such as accelerating engraftment, extending access, and examining outcomes in specific subgroups of patients. Many approaches have been investigated in the attempt to improve engraftment and survival. Variable factors have been identified, such as factors related to donor choice (human leukocyte antigen (HLA) compatibility, cell dose, and others) and transplantation (conditioning and graft-versus-host disease prophylaxis regimen). Data support that CB should be considered a reasonable option in those that do not have HLA matched sibling donor and for those in whom the time to transplant is critical.

CONCLUSIONSCB is a reasonable alternative to unrelated donor bone marrow or peripheral blood progenitor cells for transplantation. Recently developed strategies aimed at improving hematopoietic recovery and reducing early transplantation-related mortality could further improve treatment outcomes of CBT for patients with acute leukemia.